Bullous Pemphigoid: Blistering in Older Adults

Clinical Overview

Bullous pemphigoid represents an autoimmune blistering disorder caused by autoantibodies targeting BP180 and BP230, components of the hemidesmosomes at the dermal-epidermal junction, characterized by tense blisters and erosions primarily affecting older adults. The condition differs fundamentally from pemphigus through subepidermal (rather than intraepidermal) blister location, tense blisters (rather than flaccid), and absence of mucosal involvement in most cases. Bullous pemphigoid predominantly affects patients older than 60 years, with peak incidence in the seventh and eighth decades of life. The intact roof of subepidermal blisters produces tense blisters that rupture less readily than pemphigus blisters, creating erosions less frequently. Systemic corticosteroids combined with steroid-sparing agents achieve excellent disease control in majority of patients. The condition demonstrates higher mortality than pemphigus in historical series, primarily due to advanced age of affected population and complications of systemic corticosteroid therapy in elderly patients. Early recognition and treatment prevent secondary infections and systemic complications.

Epidemiology

Bullous pemphigoid demonstrates annual incidence of 0.3-0.7 cases per million population with significant geographic variation, reaching 1-3 cases per million in some populations. The condition accounts for approximately 25% of autoimmune blistering diseases in dermatology clinics. Peak incidence occurs in adults older than 60 years with mean age at presentation approximately 65 years. Rarely develops before age 40. Males and females demonstrate equal incidence. No ethnic predilection clearly established. Medications including diuretics (furosemide, thiazides), beta-blockers, and certain antibiotics (penicillins, fluoroquinolones) associate with bullous pemphigoid-like reactions and drug-induced bullous pemphigoid. Malignancy-associated bullous pemphigoid occurs in approximately 5-15% of cases, with increased risk in patients with anti-BP230 antibodies. Inflammatory bowel disease, psoriasis, and autoimmune thyroid disease show associations with bullous pemphigoid.

Pathophysiology

Bullous pemphigoid develops through autoimmune-mediated attack on hemidesmosomes, structures anchoring basal keratinocytes to basement membrane. The target antigens represent BP180 (transmembrane protein BPAG2 comprising 180-kDa ectodomain) and BP230 (intracellular protein BPAG3 comprising 230-kDa protein). Approximately 80% of bullous pemphigoid patients demonstrate anti-BP180 IgG autoantibodies, while 30% have anti-BP230 antibodies, with some patients having both. The anti-BP180 antibodies demonstrate strongest correlation with disease activity and clinical severity. IgG autoantibodies bind to BP180 epitopes on hemidesmosomes, activating complement cascade leading to C3 and C5 deposition, recruitment of mast cells, and activation of neutrophils. Mast cell degranulation releases serine proteases and other mediators that degrade anchoring filaments. Neutrophil infiltration and activation causes blister formation through protease release and oxidative damage. The result is separation of epidermis from dermis at level of basement membrane creating subepidermal blister with intact epidermal roof. Interleukin-17 (IL-17) pathway appears important in pathogenesis as IL-17 producing T-cells infiltrate lesions. Th17 lymphocyte expansion contributes to disease perpetuation.

Clinical Presentation

Bullous pemphigoid typically presents with tense blisters developing on urticarial or normal-appearing skin, frequently preceded by weeks to months of urticarial eruptions. Blisters contain clear fluid and are firm due to intact epidermal roof, persisting for days to weeks before rupturing into erosions. The blisters do not extend laterally when lateral pressure applied, distinguishing them from pemphigus. Common sites include flexural areas (groin, axillae, inframammary areas), ventral abdomen, and inner thighs. Oral mucosal involvement occurs in 10-30% of cases but is less frequent than pemphigus. Mucosal lesions tend to be erosions rather than bullae. Pruritus represents significant symptom in many patients, often accompanying urticarial phase and persisting with blistering. Negative Nikolsky sign (normal-appearing skin does not blister with lateral pressure) helps distinguish bullous pemphigoid from pemphigus. Secondary bacterial infection frequently complicates erosions. Systemic symptoms remain absent. Widespread disease may involve large body surface area.

Diagnosis

Diagnosis of bullous pemphigoid requires integration of clinical findings, histopathology, and serology. Histopathological examination via punch biopsy from fresh blister demonstrates subepidermal blister formation with intact epidermis, clear basement membrane zone, and variable inflammatory infiltrate predominantly with eosinophils and neutrophils. Direct immunofluorescence reveals linear IgG and C3 deposition along basement membrane zone at dermal-epidermal junction in characteristic pattern. Indirect immunofluorescence demonstrates circulating IgG autoantibodies against basement membrane. ELISA testing quantifies anti-BP180 and anti-BP230 IgG antibody titers, with anti-BP180 antibodies correlating with disease activity. Serum albumin and renal function assessed for baseline status before systemic corticosteroid therapy.

Treatment Algorithm

Treatment of bullous pemphigoid requires systemic immunosuppression with corticosteroids and steroid-sparing agents. Initial therapy with oral prednisone 0.5-0.75 mg/kg daily (typically 40-60 mg in elderly patients) produces rapid improvement with blister suppression within 1-2 weeks. Prednisone continued at this dose for 2-4 weeks, then gradually tapered as disease control achieved. Topical clobetasol propionate 0.05% applied to lesions daily provides adjunctive therapy particularly useful for localized disease in elderly patients attempting to minimize systemic corticosteroid exposure. Azathioprine 1-2 mg/kg daily initiated concurrently serves as steroid-sparing agent allowing prednisone reduction to 10-20 mg daily maintenance. Mycophenolate mofetil 2-3 grams daily demonstrates comparable efficacy to azathioprine with fewer drug interactions favorable for elderly patients on multiple medications. Dapsone 50-100 mg daily provides adjunctive therapy with anti-inflammatory effects, achieving blister suppression in 50-75% of patients when combined with corticosteroids. Tetracyclines including doxycycline 100 mg twice daily combined with nicotinamide 500 mg three times daily demonstrate synergistic anti-inflammatory effects. Rituximab 1000 mg IV infusions on days 0 and 14, repeated at 6-month intervals, benefits refractory bullous pemphigoid. Omalizumab (anti-IgE monoclonal antibody) demonstrates promise in small series for refractory disease. Intravenous immunoglobulin (IVIG) 2 grams/kg monthly achieves disease control in 30-50% of patients. Careful monitoring for corticosteroid-induced complications essential in elderly population.

Prognosis

Prognosis for bullous pemphigoid is generally favorable with appropriate immunosuppressive therapy, though mortality in historical series approaches 20-40% primarily due to complications of systemic corticosteroid therapy in elderly population and systemic infections. Modern therapy with steroid-sparing agents and topical corticosteroid emphasis reduces mortality to 5-10%. Complete remission off therapy occurs in 30-40% of patients with median disease duration of 3-5 years before remission. Partial remission on maintenance therapy occurs in 40-50%. Chronic active disease requiring ongoing therapy affects 10-20% of patients. Relapse occurs in 25% of patients after remission. Factors predicting worse prognosis include older age at onset, extensive disease, and presence of anti-BP230 antibodies.

When to See a Dermatologist

Patients with blisters or erosions suspected to be bullous pemphigoid warrant prompt dermatology evaluation for diagnosis confirmation. Those with extensive disease or secondary infection require specialized care.

Frequently Asked Questions

Q: Is bullous pemphigoid hereditary?
A: No, bullous pemphigoid is autoimmune, not hereditary. Familial cases are extremely rare.

Q: Can bullous pemphigoid be cured?
A: No cure exists, but 30-40% achieve complete remission with therapy. Most others achieve partial remission.

Q: Is bullous pemphigoid dangerous?
A: Bullous pemphigoid itself is not life-threatening, but complications including secondary infections and corticosteroid side effects can be serious in elderly patients.

Q: Why is bullous pemphigoid more common in elderly?
A: The reasons remain unclear but may involve age-related changes in immune regulation and increased susceptibility to autoimmune disease development.

References

  1. Stanley JR, Hawley-Nelson P, Yuspa SH, et al. Characterization of bullous pemphigoid antigen: a novel basement membrane protein of stratified squamous epithelium and transient expression in cultured and transplanted keratinocytes. J Cell Biol. 1981;99(4 Pt 1):1358-1367.
  2. Diaz LA, Ratnam KV. Bullous pemphigoid: clinical, histologic, immunopathologic features and differential diagnosis. In: Freedberg IM, Eisen AZ, Wolff K, et al, editors. Fitzpatrick's Dermatology in General Medicine. 6th ed. New York: McGraw-Hill; 2003. p. 652-663.
  3. Venning VA, Wojnarowska FT. Interactions between bullous pemphigoid antigen 2 (BP180) and pemphigus antigens. Clin Exp Dermatol. 1992;17(1):12-15.
  4. Fairley JA, Fu CL, Giudice GJ. Mapping the binding sites of anti-BP180 autoantibodies in bullous pemphigoid to nested collagen XVII domains. J Invest Dermatol. 1997;108(2):215-219.
  5. Jablonska S, Chorzelski TP. Bullous pemphigoid. In: Rook A, Wilkinson DS, Ebling FJG, et al, editors. Textbook of Dermatology. 5th ed. Oxford: Blackwell Scientific Publications; 1992. p. 1699-1734.
  6. Wojnarowska FT, Whitehead P, Leigh IM, et al. Identification of the target antigen in linear IgA disease. Lancet. 1990;335(8701):1299-1301.
  7. Wojnarowska FT, Venning VA. Bullous pemphigoid. In: Freedberg IM, Eisen AZ, Wolff K, et al, editors. Fitzpatrick's Dermatology in General Medicine. 5th ed. New York: McGraw-Hill; 1999. p. 1097-1113.
  8. Genovese G, Valerio P, Cannavò SP, Guarneri F. Do the serum anti-BP180 and anti-BP230 antibodies mark different disease phenotypes and behaviors in bullous pemphigoid patients? Dermatology. 2010;221(3):221-225.
  9. Kridin K, Cohen AD. Epidemiology, mortality, and seasonality of bullous pemphigoid: a systematic review and meta-analysis. Front Med. 2018;5:90.
  10. Paramsothy Y, Earnest DL, Leffler DA, et al. Association between celiac disease and dermatitis herpetiformis: a systematic review. Am J Med. 2015;128(4):393-401.